Incorporation of a PI3K/AKT/mTOR inhibitor functions synergistically with endocrine therapy and CDK4/6 inhibitors to inhibit tumor growth and prevent or overcome resistance to standard therapy in ER+ metastatic breast cancer. This evidence concerns the gene AKT1 and neoplasm.